NICE backs Ferring's Firmagon for prostate cancer subgroup

The U.K.'s NICE issued Firmagon degarelix from Ferring Pharmaceuticals A/S (Saint-Prex, Switzerland) to treat advanced hormone-dependent prostate cancer only in a subgroup of patients with spinal meta...